相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Panakeia's PANProfiler Colorectal (MSI/MMR) software demonstrated 93.83% agreement with standard laboratory testing in the largest real-world, multi-site validation study of AI molecular profiling to date. - The AI software successfully returned results on 86.55% of cases across 1,243 colorectal cancer patients from three UK healthcare institutions, delivering molecular biomarker analysis in minutes rather than weeks. - Published in npj Digital Medicine, the study addresses critical gaps in molecular testing access, with national audits showing substantial proportions of eligible patients experience testing delays of several weeks. - The UKCA-marked software is now deployed in UK hospitals and selected for the MHRA's AI Airlock programme, positioning it for broader healthcare system implementation.
- Flatiron Health's international oncology research network has tripled in size over the past year, now encompassing more than 30 partnerships across the UK, Germany, and Japan. - The expansion brings Flatiron's total patient database above 5 million records, with new partnerships including major academic medical centers and national cancer centers in each country. - The company established Flatiron FORUM, a global consortium addressing data transportability challenges to support multinational cancer research and regulatory decisions. - Seven research studies using multinational real-world data have been completed within the past two years, demonstrating the platform's capability for cross-country cohort analyses.
- The phase 2 PLATO-ACT4 trial demonstrated that reduced-dose intensity-modulated radiotherapy (IMRT) achieved comparable complete clinical response rates to standard dosing in early-stage anal cancer patients. - Patients receiving reduced-dose treatment experienced fewer grade 3+ toxicities (35% vs 46%), better treatment compliance, and improved sexual function scores at 6 months compared to standard dosing. - The breakthrough findings could transform clinical practice globally after 30 years of a "one-size-fits-all" approach, offering a shorter, kinder treatment option without compromising cure rates.
- The NHS Cancer Vaccine Launch Pad program will provide personalised mRNA vaccines to thousands of cancer patients across 30 hospitals in England to prevent disease recurrence. - The vaccines use mRNA technology to prime the immune system to recognise and destroy remaining cancer cells after surgery and chemotherapy treatment. - Early trials focus on melanoma, prostate, head and neck, and bowel cancers, with plans to expand to breast and lung cancers in future studies. - Father-of-four Elliot Pfebve became the first patient in England to receive a personalised bowel cancer vaccine as part of the groundbreaking trial program.
